ClinicalTrials.gov
public full text
Public Domain
Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders
A study to assess safety and efficacy of evolocumab (AMG-145) in paediatric subjects aged 10-17 years diagnosed with heterozygous familial hypercholesterolemia.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders#1454022
- Screening for Familial Hypercholesterolemia in Children#840904
- Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®#1243568
- Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia#1308778
- Healthcare activities before familial hypercholesterolemia diagnosis: a nationwide register-based study in Denmark.#13595
Record · ID 1463790
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive